HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chiharu Tohyama Selected Research

Dioxins

1/2019The role of prostaglandin E2 receptor EP1 in 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced neonatal hydronephrosis in mice.
1/2018Vocalization as a novel endpoint of atypical attachment behavior in 2,3,7,8-tetrachlorodibenzo-p-dioxin-exposed infant mice.
10/2016Polyuria-associated hydronephrosis induced by xenobiotic chemical exposure in mice.
10/2014A mouse strain less responsive to dioxin-induced prostaglandin E2 synthesis is resistant to the onset of neonatal hydronephrosis.
3/2014In utero and lactational exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin modulates dysregulation of the lipid metabolism in mouse offspring fed a high-calorie diet.
2/2014Predominant role of cytosolic phospholipase A2α in dioxin-induced neonatal hydronephrosis in mice.
6/2012Critical role of microsomal prostaglandin E synthase-1 in the hydronephrosis caused by lactational exposure to dioxin in mice.
1/2012Executive function deficits and social-behavioral abnormality in mice exposed to a low dose of dioxin in utero and via lactation.
10/2011Molecular targets that link dioxin exposure to toxicity phenotypes.
2/2009Dioxin-induced toxicity on vascular remodeling of the placenta.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Chiharu Tohyama Research Topics

Disease

14Hydronephrosis
01/2019 - 05/2003
14Body Weight (Weight, Body)
01/2019 - 02/2002
6Fetal Death
02/2009 - 02/2002
3Atrophy
02/2010 - 02/2008
3Carcinogenesis
12/2008 - 06/2003
3Hypoxia (Hypoxemia)
05/2006 - 12/2002
2Cleft Palate (Palate, Cleft)
01/2019 - 05/2003
2Hypertrophy
01/2019 - 05/2008
2Type 2 Diabetes Mellitus (MODY)
03/2014 - 11/2009
2Vascular Remodeling
02/2009 - 05/2006
2Weight Gain
05/2008 - 03/2002
2Inflammation (Inflammations)
02/2008 - 06/2004
2Cysts
05/2006 - 02/2002
2Hepatocellular Carcinoma (Hepatoma)
12/2005 - 10/2002
2Neoplasms (Cancer)
08/2004 - 01/2002
1Fibrosis (Cirrhosis)
01/2019
1Heart Diseases (Heart Disease)
01/2019
1Cardiomegaly (Heart Hypertrophy)
01/2019
1Heart Failure
01/2019
1Cardiotoxicity
01/2019
1Polyuria
10/2016
1Obesity
03/2014
1AIDS-Related Complex (ARC)
01/2012
1Precocious Puberty
05/2008
1Atopic Dermatitis (Atopic Eczema)
02/2008
1B-Cell Lymphoma (Lymphoma, B Cell)
02/2008
1Delayed Puberty
01/2005
1Hemorrhage
06/2004
1Papilloma (Papillomatosis)
06/2003
1Endometriosis
05/2003
1Acute-Phase Reaction
04/2003
1Necrosis
01/2003
1Chronic Hepatitis (Chronic Active Hepatitis)
10/2002
1Hepatitis
10/2002
1Chromosome Aberrations (Chromosome Abnormalities)
09/2002
1Infections
01/2002
1Virus Diseases (Viral Diseases)
01/2002
1Poisoning
01/2002

Drug/Important Bio-Agent (IBA)

33Polychlorinated Dibenzodioxins (TCDD)IBA
01/2019 - 01/2002
13DioxinsIBA
01/2019 - 05/2003
5Messenger RNA (mRNA)IBA
10/2014 - 04/2002
4Dinoprostone (PGE2)FDA Link
01/2019 - 02/2014
4Proteins (Proteins, Gene)FDA Link
10/2016 - 12/2002
4Cyclooxygenase 2 (Cyclooxygenase-2)IBA
10/2014 - 09/2008
3Prostaglandin-E SynthasesIBA
10/2014 - 06/2012
3Glucose (Dextrose)FDA LinkGeneric
03/2014 - 12/2002
3Cytochrome P-450 CYP1A1 (CYP1A1)IBA
04/2009 - 12/2005
3MetallothioneinIBA
12/2008 - 06/2003
2CytokinesIBA
02/2018 - 09/2008
2XenobioticsIBA
10/2016 - 09/2008
2Prostaglandins EIBA
06/2012 - 09/2008
2GlycogenIBA
05/2006 - 02/2002
2Interleukin-6 (Interleukin 6)IBA
06/2004 - 04/2003
2CadmiumIBA
01/2003 - 01/2002
2DNA (Deoxyribonucleic Acid)IBA
10/2002 - 09/2002
1Atrial Natriuretic Factor (ANF)IBA
01/2019
1Myosin Heavy Chains (Myosin Heavy Chain)IBA
01/2019
1Endothelin-1 (Endothelin 1)IBA
01/2019
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
02/2018
1LipidsIBA
02/2018
1Vasopressins (Vasopressin)IBA
10/2016
1ProstaglandinsIBA
10/2014
1Corn Oil (Oil, Corn)IBA
03/2014
1Phospholipases (Phospholipase)IBA
02/2014
1Dibutyl Phthalate (Butyl Phthalate)IBA
02/2010
1Endocrine DisruptorsIBA
02/2010
1LithiumIBA
10/2009
1ElectrolytesIBA
09/2008
1Indicators and Reagents (Reagents)IBA
05/2008
1Gonadotropin-Releasing Hormone (GnRH)FDA Link
05/2008
1Picryl Chloride (Trinitrochlorobenzene)IBA
02/2008
1Environmental Pollutants (Pollutants, Environmental)IBA
02/2008
1Immunoglobulin E (IgE)IBA
02/2008
1arseniteIBA
02/2008
1Estradiol (Delestrogen)FDA LinkGeneric
02/2008
1Dexamethasone (Maxidex)FDA LinkGeneric
02/2008
1Cytochrome P-450 Enzyme System (Cytochrome P450)IBA
10/2006
1Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA
05/2006
1SaccharinIBA
05/2005
1InterferonsIBA
12/2004
117- N,N- diethylcarbamoyl- 4- methyl- 4- azaandrostane- 3- one (DMAA)IBA
08/2004
1ArsenicIBA
08/2004
1LipopolysaccharidesIBA
06/2004
1InterleukinsIBA
06/2004
1Hemostatics (Antihemorrhagics)IBA
06/2004
1EndotoxinsIBA
06/2004
1Acetates (Acetic Acid Esters)FDA Link
06/2003
1Codon (Codons)IBA
06/2003
1anthraceneIBA
06/2003
1Pregnancy ProteinsIBA
12/2002
1CopperIBA
10/2002
1Androgen Receptors (Androgen Receptor)IBA
04/2002
1CarcinogensIBA
01/2002

Therapy/Procedure

1Ovariectomy (Oophorectomy)
05/2008
1Ligation
12/2002
1Aftercare (After-Treatment)
03/2002
1Oral Administration
02/2002